President-elect Donald Trump’s plan to nominate Robert F. Kennedy Jr. as secretary of the US Department of Health and Human Services was not entirely unexpected, but it sent biopharmaceutical stock valuations plummeting, nonetheless. Biotechnology stock indices and exchange-traded funds sank in the afternoon on 14 November immediately after the announcement and continued to fall on 15 November.
Finance Watch: Biopharma Stocks Sink On RFK Jr. Nomination To Head HHS
Telix Lists In The US, Medicus Launches IPO
Public Company Edition: President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to lead the US Department of Health and Human Services is seen as raising the potential for regulatory risk. Also, Geron revealed up to $375m in royalty and debt financings, while Zai Lab grossed $200m in a FOPO.
More from Finance Watch
More from Scrip
• By
Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?
• By
In this week's episode: Merck & Co. licenses Hengrui’s lipid lowerer; Novo gets United’s triple G obesity drug; J&J plans major US manufacturing investments; approval for GSK’s novel antibiotic; and a call for more aggressive Korean M&A activity.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.